The federal body that runs Belgium's compulsory health insurance. The sickness funds pay patients back under its rules; its lists set which medicines are reimbursed, and since January 2026 it runs an early access route for innovative medicines.
RIZIV-INAMI manages the compulsory health care and benefits insurance. Its own pages describe the system as one of negotiation: the sickness funds (mutualités), which reimburse care and pay benefits, the care providers, employers and trade unions sit on its committees, and the insurance is 75% financed by social security contributions. A patient pays a personal share (ticket modérateur) for many services, capped each year by the maximum billing scheme (MàF), whose ceiling depends on household income; it is fixed at 450 euros (indexed) for households with increased reimbursement, lowered in 2022 to 250 euros for the lowest-income households, and reduced by 100 euros (indexed) for a household with a chronic patient.
For medicines, its Commission for the Reimbursement of Medicines advises on reimbursement, and agreements under articles 81 and 111 are concluded for some innovative medicines; the public parts of those agreements are now published in a web application, a transparency reform the insurer counts among those completed in 2024. A reform roadmap approved in January 2024 brought patient representatives into the Commission from 1 April 2025, started the Early and Equitable Fast Access procedure on 1 January 2026, under which the insurance pays a temporary flat amount per patient for a medicine a company provides free, and plans an added-value classification from 1 January 2027. Its Special Solidarity Fund can pay for an innovative medicine in an unmet medical need cohort. With the Netherlands, Luxembourg, Austria and Ireland it takes part in the BeNeLuxA collaboration on joint assessment and negotiation. It also funds the multidisciplinary oncology consultation, the concentration of complex pancreatic and oesophageal surgery in reference centres, and a temporary agreement covering about fifty unreimbursed medicines for children with cancer from 2024 to 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/